CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of life sciences executive Lisa Ricciardi to the newly created position of senior vice president, corporate and business development. In this role, Ms. Ricciardi will be responsible for overseeing the company’s biopharmaceutical partnerships as well as corporate and business development activities across the company.
“Lisa brings a tremendous level of experience and expertise in areas that will help Foundation Medicine further its vision to transform cancer care,” commented Steven J. Kafka, Ph.D., chief operating officer of Foundation Medicine. “Her leadership will help us to accelerate the advancement of our new product pipelines for both clinical and technology products, and to explore new collaborative opportunities that we expect will increase our impact for patients and other key stakeholders, while also driving shareholder value.”
Prior to joining Foundation Medicine, Ms. Ricciardi held numerous senior business development and marketing roles in pharmaceuticals, healthcare services, and finance. Ms. Ricciardi spent several years at Pfizer culminating in the role of senior vice president, licensing and development, where she led more than two dozen complex, multinational, multi-year deals across a host of disease areas, including oncology. Ms. Ricciardi was also a venture partner for Essex Woodlands Health Ventures, and served as senior vice president of U.S. and international business development in the healthcare services sector at Medco Health Solutions. Most recently, Ms. Ricciardi served as a consultant to the specialty pharmacy division of DaVita, a full-service pharmacy specializing in renal care.
Ms. Ricciardi is currently a member of the Board of Directors of United Drug Group, PLC in Dublin, Ireland, and a director with Chimerix in Durham, North Carolina. Ms. Ricciardi earned an MBA from the University of Chicago and a bachelor’s degree with honors from Wesleyan University in Middletown, Connecticut.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.